These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23252355)

  • 1. Delivering cost-effective care for COPD in the USA: recent progress and current challenges.
    Breunig IM; Shaya FT; Scharf SM
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):725-31. PubMed ID: 23252355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
    Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
    Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving in-office discussion of chronic obstructive pulmonary disease: results and recommendations from an in-office linguistic study in chronic obstructive pulmonary disease.
    Nelson M; Hamilton HE
    Am J Med; 2007 Aug; 120(8 Suppl 1):S28-32. PubMed ID: 17678941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
    Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
    COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telehealthcare management for patients with chronic obstructive pulmonary disease.
    Yohannes AM
    Expert Rev Respir Med; 2012 Jun; 6(3):239-42. PubMed ID: 22788935
    [No Abstract]   [Full Text] [Related]  

  • 7. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
    Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
    Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2007 GOLD Guidelines: a comprehensive care framework.
    Gold PM
    Respir Care; 2009 Aug; 54(8):1040-9. PubMed ID: 19650945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
    Simoens S; Decramer M; Laekeman G
    Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
    Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
    Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH
    Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
    Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
    J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of care for COPD by Japanese physicians.
    Fukuhara S; Nishimura M; Nordyke RJ; Zaher CA; Peabody JW
    Respirology; 2005 Jun; 10(3):341-8. PubMed ID: 15955147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and humanistic issues related to treatment of acute bronchospasm.
    Okamoto LJ
    Pharmacotherapy; 2006 Sep; 26(9 Pt 2):175S-80S. PubMed ID: 16945064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPD exacerbations.
    Burt L; Corbridge S
    Am J Nurs; 2013 Feb; 113(2):34-43; quiz 44. PubMed ID: 23334561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of primary care in early diagnosis and effective management of COPD.
    Bellamy D; Smith J
    Int J Clin Pract; 2007 Aug; 61(8):1380-9. PubMed ID: 17627713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost impact of COPD in Japan: opportunities and challenges?
    Nishimura S; Zaher C
    Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
    Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
    Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.